You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 4
  • EPV129/#529 Long-term clinical and economic value of pembrolizumab + lenvatinib compared with chemotherapy in previously treated advanced endometrial cancer patients in Sweden: a cost-effectiveness analysis

Article metrics

Article menu

Download PDFPDF

E-Posters
E-Poster Viewing
EPV129/#529 Long-term clinical and economic value of pembrolizumab + lenvatinib compared with chemotherapy in previously treated advanced endometrial cancer patients in Sweden: a cost-effectiveness analysis
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to October 2024

AbstractFullPdf
Nov 202165020
Dec 202154019
Jan 20223707
Feb 202240011
Mar 202276016
Apr 202251015
May 202248015
Jun 20224909
Jul 202236013
Aug 20223809
Sep 202296019
Oct 202237014
Nov 20223207
Dec 20223004
Jan 20233809
Feb 20233108
Mar 20235608
Apr 20232004
May 20231804
Jun 20232503
Jul 202354012
Aug 20234104
Sep 2023402
Oct 20231406
Nov 202352017
Dec 20233104
Jan 20242403
Feb 20242204
Mar 202430011
Apr 20243007
May 20241200
Jun 20243806
Jul 20242404
Aug 20241606
Sep 20242208
Oct 2024201
Total12930309